Novel Coronavirus was identified near the end of 2019, presenting with a spectrum of symptoms including febrile illness, cough, severe pneumonia, and in some patients, death. The pathogen is now widely called Coronavirus disease 2019 (COVID-19) and has rapidly turned into a global pandemic since originally being identified in Wuhan, China. Coronaviridae is the family of single-stranded (+ssRNA), pleomorphic, enveloped RNA viruses that consists of the Coronavirus genus \[[@b1-ad-11-3-509]\]. COVID-19 is also referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to the genomic and symptomatic similarities with the SARS-CoV that caused an epidemic in 2002-2004 \[[@b2-ad-11-3-509]\]. SARS-CoV-2 is predominantly spread by person-to-person contact via virally loaded respiratory droplets \[[@b3-ad-11-3-509]\]. However, the transmission may also occur by touching contaminated surfaces and subsequently touching one\'s eyes, nose, or mouth \[[@b4-ad-11-3-509], [@b5-ad-11-3-509]\]. The incubation period, the period before the first symptoms present itself, is on average of 4-5 days, with 95% presenting within 12.5 days \[[@b6-ad-11-3-509],[@b7-ad-11-3-509]\].

The World Health Organization (WHO) reported 2,920,905 confirmed infected, and 203,269 COVID-19 related deaths globally as of April 25th, 2020 \[[@b8-ad-11-3-509]\]. Drastic measures to combat SARS-CoV-2 are warranted due to its contagiousness, viability, and higher death toll compared to its predecessor SARS-CoV. Although SARS-CoV had a significantly higher case-fatality (around 10%) \[[@b9-ad-11-3-509]\], the virus was not viable enough to remain in the human population and never spread in the United States and other countries like SARS-CoV-2 \[[@b10-ad-11-3-509]\]. SARS-CoV-2, on the other hand, appears to rapidly spread, which is contributing to its global spread and a significantly higher number of cases.

Severe and critical cases of COVID-19 disproportionately affect middle-aged and older/aged populations, with increased mortality in aged adults \[[@b11-ad-11-3-509]\]. Illness severity ranges from asymptomatic, mild, severe, and critical. Mild illness is characterized as no to mild pneumonia \[[@b11-ad-11-3-509]\]. The severe disease presents with dyspnea, hypoxia, or \>50% lung involvement, and critical illness occurs when there is respiratory failure, shock, or multiorgan failure \[[@b11-ad-11-3-509]\]. The Centers for Disease Control and Prevention (CDC) and the WHO estimate the mortality rates of SARS-CoV-2 to be around 3.4% and case fatality rates (CFR) may increase up to 10-27 % in individuals 80 years old or older \[[@b8-ad-11-3-509], [@b12-ad-11-3-509]\]. SARS-CoV-2 is a novel virus, and very little is known about it. In such a scenario, it is crucial to understand the COVID-19 pathobiology to identify the innovative treatment strategy. Our laboratory and others have reported that miRNAs play a critical role in age-related complications \[[@b13-ad-11-3-509]-[@b16-ad-11-3-509]\].

MiRNAs play a vital role in the pathogenesis of various diseases, including viral infections, disease progression, and inhibition \[[@b17-ad-11-3-509]-[@b23-ad-11-3-509]\]. MicroRNAs are small noncoding RNAs, bind to 3\'UTR of mRNA, and inhibit translation or induce degradation of mRNAs \[[@b19-ad-11-3-509], [@b21-ad-11-3-509], [@b23-ad-11-3-509]\]. Recent studies suggested that host cellular miRNAs can directly target both viral 3'UTR and coding region of the viral genome to induce antiviral effect \[[@b19-ad-11-3-509], [@b21-ad-11-3-509], [@b23-ad-11-3-509]\]. For example, the number of groups previously reported that host miRNAs (miR-323, miR-491, miR-485, miR-654, and miR-3145) bind to influenza PB1 gene coding region, degrade RNA and inhibit viral translation and reduce the accumulation of viral particles \[[@b19-ad-11-3-509], [@b24-ad-11-3-509], [@b25-ad-11-3-509]\]. Furthermore, the host cellular miRNA-29a inhibit Human immunodeficiency virus type 1 (HIV-1) nef protein expression and thus, inhibit viral replication \[[@b26-ad-11-3-509]\]. On the contrary, some groups also suggested the positive effect of host miRNAs on viral replication. For example, miR-122 binding to 3' and 5' UTR of hepatotropic virus RNA and increase viral RNA stability leads to viral propagation \[[@b18-ad-11-3-509], [@b20-ad-11-3-509], [@b22-ad-11-3-509]\]. Based on the above reports, we did *in silico* analysis of miRNAs targeting SARS and COVID-19 (recent isolates from different regions) to understand the pathophysiology and identify novel therapeutic targets.

###### 

Details of SARS and COVID-19 isolates from different geographic locations, sequence length, and the number of human miRNA targets.

  --------------------------------------------------------------------------------------------------------------------------------
  Virus type   GenBank ID       Location         Month and year of isolates/sequenced   Sequence Length\   Number of miR Targets
                                                                                        (Nucleotides)      
  ------------ ---------------- ---------------- -------------------------------------- ------------------ -----------------------
  SARS         AY338175.1       Taiwan           July 2003                              29573              855

  SARS         AY348314.1       Taiwan           July 2003                              29573              855

  SARS         AY291451.1       Taiwan           July 2003                              29729              858

  SARS         NC_004718.3      Canada           April 2003                             29751              857

  COVID -19    EPI_ISL_406798   Wuhan/China      December 2019                          29866              893

  COVID -19    EPI_ISL_403929   Wuhan/China      December 2019                          29890              900

  COVID -19    EPI_ISL_402121   Wuhan/China      December 2019                          29891              898

  COVID -19    EPI_ISL_402123   Wuhan/China      December 2019                          29899              900

  COVID -19    EPI_ISL_403931   Wuhan/China      December 2019                          29889              903

  COVID -19    EPI_ISL_403930   Wuhan/China      December 2019                          29899              899

  COVID -19    NC_045512.2      Wuhan (China)    January 2020                           29903              900

  COVID -19    MT007544.1       Australia        January 2020                           29893              902

  COVID -19    EPI_ISL_406862   Germany          January 2020                           29782              896

  COVID -19    EPI_ISL_403962   Thailand         January 2020                           29848              897

  COVID -19    EPI_ISL_412974   Italy            January 2020                           29903              900

  COVID -19    EPI_ISL_407893   Australia        January 2020                           29782              898

  COVID -19    EPI_ISL_406223   Arizona/USA      January 2020                           29882              900

  COVID -19    EPI_ISL_406597   France           January 2020                           29809              901

  COVID -19    EPI_ISL_420799   S. Korea         February 2020                          29882              901

  COVID -19    EPI_ISL_413214   Australia        February 2020                          29782              899

  COVID -19    EPI_ISL_419211   Isreal           February 2020                          29851              897

  COVID -19    MT050493.1       India            Fenruary 2020                          29851              895

  COVID -19    MT066176.1       Taiwan           February 2020                          29870              900

  COVID -19    EPI_ISL_418001   Portugal         March 2020                             29763              895

  COVID -19    EPI_ISL_417507   USA              March 2020                             29782              898

  COVID -19    MT159718.1       USA (Cruise A)   March 2020                             29882              900

  COVID -19    MT126808.1       Brazil           March 2020                             29876              900

  COVID -19    EPI_ISL_428847   Singapore        April 2020                             29888              900

  COVID -19    EPI_ISL_426565   Arizona/USA      April 2020                             29882              897

  COVID -19    EPI_ISL_420144   Georgia          April 2020                             29833              900

  COVID -19    EPI_ISL_427391   Turkey           April 2020                             29895              899

  COVID -19    EPI_ISL_429223   Switzerland      April 2020                             29894              895

  COVID -19    EPI_ISL_422601   Netherland       April 2020                             29775              902
  --------------------------------------------------------------------------------------------------------------------------------

MATERIALS AND METHODS
=====================

Viral genome sequence retrieval, homology, and phylogenetic analyses
--------------------------------------------------------------------

The complete genome sequences of the SARS and COVID-19 isolates were retrieved from the GenBank database. We retrieved four SARS and 29 COVID-19 sequences from NCBI and GISAID for for homology and phylogenetic analysis. Details of sequence identification are summarizing in [Table 1](#T1-ad-11-3-509){ref-type="table"}. The sequences were aligned using the Multiple Sequence Alignment tool at Clustal Omega 1.2.3 on Geneious Prime 2020.1.1. The phylogenetic alignment tree generated using the neighbor-joining method.

COVID-19 genome and human MiRNA target analysis
-----------------------------------------------

As previously mentioned above, miRNAs are known to target 3\'UTR and coding sequences and prevent mRNA translation or degrade RNA. Keeping this in consideration, we used the whole viral genome sequence for miRNA target analysis. We used miRDB (<http://www.mirdb.org/>) software to identify novel human miRNAs targeting the COVID-19 viral genome \[[@b27-ad-11-3-509], [@b28-ad-11-3-509]\]. Furthermore, we used this data to correlate with the existing literature.

GO, and KEGG pathway analysis
-----------------------------

Gene Ontology (GO) and KEGG signaling pathway analyses were performed on human microRNAs targeting the COVID-19 genome using DIANA-miRPath v 3.0 (<http://diana.imis.athena-innovation.gr/DianaTools/index.php>) \[[@b29-ad-11-3-509]\]. We used miRNAs with a target score above 90 because these miRNAs have high probability of being real targets \[[@b27-ad-11-3-509], [@b28-ad-11-3-509]\].

RESULTS
=======

Viral genome sequence homology and phylogenetic analyses
--------------------------------------------------------

The sequences of the COVID-19 isolates have been stored, compiled, and analyzed by various sources; one of the major resources for these sequences has been the Global Initiative on Sharing All Influenza Data (GISAID), which is a public-private initiative initially made for sharing sequences of influenza data. The organization provides a complete daily analysis of the viruses uploaded by the various researchers across the Globe. The COVID-19 belongs to a family of RNA viruses, which are very stable, unlikely other RNA viruses common to us, such as Human Immunodeficiency Virus (HIV), and Foot and Mouth Diseases Virus (FMDV).

###### 

Sequence homology between the SARS and COVID-19 isolates from different geographic locations.

                   AY291451.1   NC_004718.3   AY338175.1   AY348314.1   MT007544.1   EPI_ISL_429223   EPI_ISL_418001   EPI_ISL_420144   EPI_ISL_428847   EPI_ISL_427391   EPI_ISL_426565   EPI_ISL_403931   EPI_ISL_422601   MT050493.1   EPI_ISL_413214   EPI_ISL_419211   EPI_ISL_417507   EPI_ISL_406862   EPI_ISL_420799   EPI_ISL_402123   EPI_ISL_406223   EPI_ISL_407893   EPI_ISL_406597   EPI_ISL_406798   MT066176.1   MT126808.1   MT159718.1   EPI_ISL_402121   EPI_ISL_412974   EPI_ISL_403930   EPI_ISL_403962   EPI_ISL_403929   NC_045512.2
  ---------------- ------------ ------------- ------------ ------------ ------------ ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ------------ ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ------------ ------------ ------------ ---------------- ---------------- ---------------- ---------------- ---------------- -------------
  AY291451.1                    100           100          100          78.8         78.8             78.7             78.7             78.8             78.7             78.8             78.8             78.8             78.8         78.8             78.8             78.8             78.8             78.8             78.8             78.8             78.8             78.8             78.8             78.8         78.8         78.8         78.8             78.8             78.8             78.8             78.8             78.8
  NC_004718.3      100                        100          100          78.8         78.8             78.7             78.7             78.8             78.7             78.8             78.8             78.7             78.8         78.8             78.8             78.7             78.8             78.8             78.8             78.8             78.8             78.7             78.8             78.8         78.8         78.8         78.8             78.8             78.8             78.8             78.8             78.8
  AY338175.1       100          100                        100          78.7         78.7             78.7             78.7             78.7             78.7             78.7             78.7             78.7             78.7         78.7             78.7             78.7             78.7             78.7             78.7             78.7             78.7             78.7             78.7             78.7         78.7         78.7         78.7             78.7             78.7             78.7             78.7             78.7
  AY348314.1       100          100           100                       78.7         78.7             78.7             78.7             78.7             78.7             78.7             78.7             78.7             78.7         78.7             78.7             78.7             78.7             78.7             78.7             78.7             78.7             78.7             78.7             78.7         78.7         78.7         78.7             78.7             78.7             78.7             78.7             78.7
  MT007544.1       78.8         78.8          78.7         78.7                      99.9             99.9             99.9             99.9             99.8             99.9             99.9             99.9             99.9         99.9             99.9             99.9             99.9             99.9             99.9             99.9             99.9             100              99.9             99.9         99.9         99.9         99.9             100              100              100              100              100
  EPI_ISL_429223   78.8         78.8          78.7         78.7         99.9                          100              100              99.9             99.9             100              99.9             100              99.9         100              100              100              100              100              100              100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_418001   78.7         78.7          78.7         78.7         99.9         100                               100              99.9             100              100              100              100              100          100              100              100              100              100              100              100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_420144   78.7         78.7          78.7         78.7         99.9         100              100                               99.9             99.9             100              100              100              100          100              100              100              100              100              100              100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_428847   78.8         78.8          78.7         78.7         99.9         99.9             99.9             99.9                              99.9             99.9             100              99.9             100          100              100              100              100              100              100              100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_427391   78.7         78.7          78.7         78.7         99.8         99.9             100              99.9             99.9                              99.9             99.9             100              99.9         99.9             99.9             99.9             100              99.9             99.9             99.9             100              99.9             99.9             99.9         99.9         99.9         99.9             99.9             99.9             99.9             99.9             99.9
  EPI_ISL_426565   78.8         78.8          78.7         78.7         99.9         100              100              100              99.9             99.9                              99.9             100              99.9         100              100              100              100              100              100              100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_403931   78.8         78.8          78.7         78.7         99.9         99.9             100              100              100              99.9             99.9                              100              100          100              100              100              100              100              100              100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_422601   78.8         78.7          78.7         78.7         99.9         100              100              100              99.9             100              100              100                               100          100              100              100              100              100              100              100              100              100              100              100          100          100          100              100              100              100              100              100
  MT050493.1       78.8         78.8          78.7         78.7         99.9         99.9             100              100              100              99.9             99.9             100              100                           100              100              100              100              100              100              100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_413214   78.8         78.8          78.7         78.7         99.9         100              100              100              100              99.9             100              100              100              100                           100              100              100              100              100              100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_419211   78.8         78.8          78.7         78.7         99.9         100              100              100              100              99.9             100              100              100              100          100                               100              100              100              100              100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_417507   78.8         78.7          78.7         78.7         99.9         100              100              100              100              99.9             100              100              100              100          100              100                               100              100              100              100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_406862   78.8         78.8          78.7         78.7         99.9         100              100              100              100              100              100              100              100              100          100              100              100                               100              100              100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_420799   78.8         78.8          78.7         78.7         99.9         100              100              100              100              99.9             100              100              100              100          100              100              100              100                               100              100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_402123   78.8         78.8          78.7         78.7         99.9         100              100              100              100              99.9             100              100              100              100          100              100              100              100              100                               100              100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_406223   78.8         78.8          78.7         78.7         99.9         100              100              100              100              99.9             100              100              100              100          100              100              100              100              100              100                               100              100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_407893   78.8         78.8          78.7         78.7         99.9         100              100              100              100              100              100              100              100              100          100              100              100              100              100              100              100                               100              100              100          100          100          100              100              100              100              100              100
  EPI_ISL_406597   78.8         78.7          78.7         78.7         100          100              100              100              100              99.9             100              100              100              100          100              100              100              100              100              100              100              100                               100              100          100          100          100              100              100              100              100              100
  EPI_ISL_406798   78.8         78.8          78.7         78.7         99.9         100              100              100              100              99.9             100              100              100              100          100              100              100              100              100              100              100              100              100                               100          100          100          100              100              100              100              100              100
  MT066176.1       78.8         78.8          78.7         78.7         99.9         100              100              100              100              99.9             100              100              100              100          100              100              100              100              100              100              100              100              100              100                           100          100          100              100              100              100              100              100
  MT126808.1       78.8         78.8          78.7         78.7         99.9         100              100              100              100              99.9             100              100              100              100          100              100              100              100              100              100              100              100              100              100              100                       100          100              100              100              100              100              100
  MT159718.1       78.8         78.8          78.7         78.7         99.9         100              100              100              100              99.9             100              100              100              100          100              100              100              100              100              100              100              100              100              100              100          100                       100              100              100              100              100              100
  EPI_ISL_402121   78.8         78.8          78.7         78.7         99.9         100              100              100              100              99.9             100              100              100              100          100              100              100              100              100              100              100              100              100              100              100          100          100                           100              100              100              100              100
  EPI_ISL_412974   78.8         78.8          78.7         78.7         100          100              100              100              100              99.9             100              100              100              100          100              100              100              100              100              100              100              100              100              100              100          100          100          100                               100              100              100              100
  EPI_ISL_403930   78.8         78.8          78.7         78.7         100          100              100              100              100              99.9             100              100              100              100          100              100              100              100              100              100              100              100              100              100              100          100          100          100              100                               100              100              100
  EPI_ISL_403962   78.8         78.8          78.7         78.7         100          100              100              100              100              99.9             100              100              100              100          100              100              100              100              100              100              100              100              100              100              100          100          100          100              100              100                               100              100
  EPI_ISL_403929   78.8         78.8          78.7         78.7         100          100              100              100              100              99.9             100              100              100              100          100              100              100              100              100              100              100              100              100              100              100          100          100          100              100              100              100                               100
  NC_045512.2      78.8         78.8          78.7         78.7         100          100              100              100              100              99.9             100              100              100              100          100              100              100              100              100              100              100              100              100              100              100          100          100          100              100              100              100              100              

However, GISAID showed a constant drift in the COVID-19 population-based upon three specific mutations in its genome. To assimilate different sequences, we chose 29 genome sequences of COVID-19 from five continents covering 17 countries ([Table 1](#T1-ad-11-3-509){ref-type="table"}). To gather the most diverse sequences, we collected these sequences based upon their date of isolation. Among 29 viral sequences, six isolated in 2019, and the remaining 23 were isolated at different months of 2020 from January to April ([Table 1](#T1-ad-11-3-509){ref-type="table"}). These 29 COVID-19 sequences were compared with the four SARS genome sequences to evaluate the differences between the COVID-19 and SARS and among different isolates of COVID-19. The sequences were analyzed using Geneious Prime 2020.1.1. The data suggested the SARS genomes are approximately 78.7% similar to the COVID-19 sequences ([Table 2](#T2-ad-11-3-509){ref-type="table"}). All 29 sequences of COVID-19 are very similar (99.9% - 100% sequence similarity). Phylogenetic analysis showed that COVID-19 is closely related to SARS isolates but still genetically different ([Fig. 1](#F1-ad-11-3-509){ref-type="fig"}). All 29 COVID-19 isolates are close to each other with little change in sequence. Since variability among different COVID-19 isolates was minimal, we calculated the number of different individual nucleotides in each COVID-19 isolates that revealed a total nucleotide difference among these COVID-19 is from 1-55 nucleotides in the entire genome of approximately 29kb ([Supplementary Table 1](#SD1-ad-11-3-509){ref-type="supplementary-material"}). The most diverse sequence that has a difference of 55 nucleotides were between the isolates from Australia (MT007544.1) and Turkey (EPI_ISL_427391) isolated in 2019 and April 2020, respectively ([Fig. 1](#F1-ad-11-3-509){ref-type="fig"} & [Table 2](#T2-ad-11-3-509){ref-type="table"}, [Supplementary Table 1](#SD1-ad-11-3-509){ref-type="supplementary-material"}).

Figure 1.**Phylogenetic analysis of Coronavirus isolates from different geographic locations**. The phylogenetic analysis shows sequence relatedness among COVID-19 isolates (blue) and SARS isolates (black).

###### 

List of human miRNAs with higher target score (above 94), the number of binding sites, and miRNAs seed binding site on COVID-19 isolates.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  miRNAs        Target Score   Number of Sites and Seed locations of miRNAs and COVID-19 genome binding sites
  ------------- -------------- ------------------------------------------------------------------------------------------------------------------------
  miR-15b-5p\   99             16 SITES (3163, 5384, 8458, 8614, 13090, 14562, 14781, 19857, 24094, 24634, 25683, 26723, 28921, 28935, 28938, 29023)\
  miR-15a-5p                   (Note: miR-15b-5p, and miR-15a-5p have same target site)

  miR-548c-5p   97             15 SITES (2733, 4025, 4531, 6783, 7774, 9508, 10962, 11641, 11672, 12950, 13644, 20196, 21886, 23026, 25807)

  miR-548d-3p   94             13 SITES (6960, 7245, 7272, 8927, 11540, 13459, 15517, 15814, 18367, 21100, 22217, 22583, 26653)

  miR-409-3p    96             12 SITES (4990, 8386, 11785, 12403, 12525, 17285, 19760, 19803, 20759, 20829, 28767, 29694)

  miR-30b-5p    95             14 SITES (3451, 4974, 7939, 9354, 10426, 11657, 16863, 19567, 19710, 20069, 20360, 26729, 27955, 28140)

  miR-505-3p    95             11 SITES (152, 8488, 10609, 10792, 14208, 15648, 17580, 18123, 18156, 18612, 18906)
  -----------------------------------------------------------------------------------------------------------------------------------------------------

MicroRNAs targeting SARS and COVID-19 genome
--------------------------------------------

As we mentioned above, we performed miRNA analysis on the whole genome of SARS and COVID-19 due to the efficiency of miRNAs targeting both 3\'UTR and coding region. Our analysis found some interesting results. We found 848 common miRNAs targeting the SARS genome (four isolates, NC_004718.3, AY291451, AY338175, AY348314) and 873 common microRNAs targeting the 29 isolates of COVID-19 genome ([Supplementary Table 2](#SD1-ad-11-3-509){ref-type="supplementary-material"}). Out of a total of 848 miRNAs from SARS, only 558 commonly present in all COVID-19 isolates ([Fig. 2](#F2-ad-11-3-509){ref-type="fig"}, [Supplementary Table 2](#SD1-ad-11-3-509){ref-type="supplementary-material"}). Interestingly, 315 miRNAs are unique for COVID-19 isolates and 290 miRNAs unique to SRAS ([Fig. 2](#F2-ad-11-3-509){ref-type="fig"}). Furthermore, the COVID-19 targeting miRNAs with a higher target score (above 94) showed more than ten target sites and maximum complementary miRNA-RNA seed paring (\~6-8 nucleotide seed base pairing) ([Table 3](#T3-ad-11-3-509){ref-type="table"}). We also noted that out of 29 COVID-19 isolates, 19 have identical miRNA targets ([Table 4](#T4-ad-11-3-509){ref-type="table"}). Ten isolates have unique miRNAs targets. Among ten isolates, Netherland (EPI_ISL_422601), Australia (EPI_ISL_413214), and Wuhan (EPI_ISL_403931) showed six, four, and four unique miRNAs targets respectively. The detail is given in the table ([Table 4](#T4-ad-11-3-509){ref-type="table"}).

###### 

Summary of important findings on human miRNAs targeting SARS and COVID-19 genome.

  Serial. No   Important findings on human miRNAs targeting Coronavirus
  ------------ -------------------------------------------------------------------------------------------------------------------------------------------
  1            848 miRNAs are common in SARS
  2            873 miRNAs are common inCOVID-19
  3            558 miRNAs are common between SARS and COVID-19
  4            315 miRNAs are unique to COVID-19
  5            290 miRNAs are unique to SARS
  6            10 COVID-19 isolates have some unique miR targets
  7            MT050493.1 (India): 1 unique miRNA (hsa-miR-449c-3p)
  8            MT007544.1 (Australia): 2 unique miRNAs (hsa-miR-4538, hsa-miR-4453)
  9            EPI_ISL_402121 (Wuhan/China): 1 unique miRNA (hsa-miR-5590-5p)
  10           EPI_ISL_402123 (Wuhan/China): 1 unique miRNA (hsa-miR-106a-3p)
  11           EPI_ISL_420799 (South Korea): 1 unique miRNA (hsa-miR-4641)
  12           EPI_ISL_427391 (Turkey): 1 unique miRNA (hsa-miR-496)
  13           EPI_ISL_429223 (Switzerland): 1 unique miRNA (hsa-miR-146b-3p)
  14           EPI_ISL_403931 (Wuhan): 4 unique miRNAs (hsa-miR-4474-3p, hsa-miR-6762-3p, hsa-miR-10401-5p, hsa-miR-4304)
  15           EPI_ISL_413214 (Australia): 4 unique miRNAs (hsa-miR-5088-5p, hsa-miR-9900, hsa-miR-3677-5p, hsa-miR-892c-5p)
  16           EPI_ISL_422601 (Netherland): 6 unique miRNAs (hsa-miR-4666a-3p, hsa-miR-98-3p, hsa-let-7b-3p, hsa-let-7a-3p, hsa-miR-381-3p, hsa-miR-300)

###### 

Human miRNAs targeting the COVID-19 genome regulating KEGG pathway.

  KEGG pathway                                                 p-value    \#genes   \#miRNAs
  ------------------------------------------------------------ ---------- --------- ----------
  Proteoglycans in cancer                                      5.75E-08   145       76
  Hippo signaling pathway                                      1.04E-07   113       74
  Arrhythmogenic right ventricular cardiomyopathy (ARVC)       6.54E-07   57        72
  Adherens junction                                            6.54E-07   62        75
  Renal cell carcinoma                                         2.40E-06   56        74
  Wnt signaling pathway                                        2.99E-06   107       76
  Fatty acid biosynthesis                                      1.25E-05   9         50
  ECM-receptor interaction                                     1.25E-05   56        70
  Axon guidance                                                1.58E-05   94        75
  FoxO signaling pathway                                       4.68E-05   100       76
  Ubiquitin mediated proteolysis                               5.75E-05   102       76
  Pathways in cancer                                           6.76E-05   275       76
  ErbB signaling pathway                                       8.02E-05   66        75
  Pancreatic cancer                                            0.000165   53        73
  TGF-beta signaling pathway                                   0.000234   57        73
  Focal adhesion                                               0.000234   147       74
  Rap1 signaling pathway                                       0.000234   148       76
  Gap junction                                                 0.000753   64        76
  Long-term depression                                         0.000962   45        73
  N-Glycan biosynthesis                                        0.001119   33        69
  Prion diseases                                               0.001166   20        66
  Endocytosis                                                  0.001469   140       75
  Fatty acid metabolism                                        0.001547   31        69
  Endometrial cancer                                           0.001567   41        72
  Signaling pathways regulating pluripotency of stem cells     0.001567   99        76
  Prostate cancer                                              0.001769   66        75
  Colorectal cancer                                            0.002458   49        72
  Cell cycle                                                   0.002703   89        73
  PI3K-Akt signaling pathway                                   0.002703   225       76
  Melanoma                                                     0.00405    54        73
  Circadian rhythm                                             0.00591    26        70
  Prolactin signaling pathway                                  0.006364   50        75
  Adrenergic signaling in cardiomyocytes                       0.006716   97        77
  Glycosaminoglycan biosynthesis - heparan sulfate / heparin   0.006964   17        62
  Dorso-ventral axis formation                                 0.011682   23        73
  AMPK signaling pathway                                       0.012171   87        75
  Glioma                                                       0.012308   45        72
  Tight junction                                               0.012616   98        76
  Thyroid hormone signaling pathway                            0.01495    79        72
  Morphine addiction                                           0.01495    63        73
  Oocyte meiosis                                               0.01495    79        75
  Ras signaling pathway                                        0.01495    145       76
  Lysine degradation                                           0.016507   33        66
  Amphetamine addiction                                        0.016687   45        72
  Sphingolipid signaling pathway                               0.016687   79        76
  Glutamatergic synapse                                        0.016687   77        76
  mRNA surveillance pathway                                    0.01713    64        74
  RNA transport                                                0.01833    112       75
  MAPK signaling pathway                                       0.018745   166       77
  Chronic myeloid leukemia                                     0.01925    51        74
  Estrogen signaling pathway                                   0.022066   65        76
  GABAergic synapse                                            0.023522   59        73
  p53 signaling pathway                                        0.026352   48        73
  Biosynthesis of unsaturated fatty acids                      0.027342   15        49
  mTOR signaling pathway                                       0.031797   45        70
  Regulation of actin cytoskeleton                             0.037298   139       75
  Protein processing in endoplasmic reticulum                  0.038084   112       74
  cAMP signaling pathway                                       0.038084   130       76
  Oxytocin signaling pathway                                   0.038084   104       77
  Glycosaminoglycan biosynthesis - keratan sulfate             0.039424   12        23
  Central carbon metabolism in cancer                          0.04664    46        70
  Melanogenesis                                                0.04852    68        76

Figure 2.Common and different human miRNAs targeting SARS and COVID-19 isolates from different geographic locations.

GO and KEGG pathway analysis of miRNAs targeting COVID-19
---------------------------------------------------------

To identify the functional relevance of human miRNAs targeting COVID-19, we performed Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation and GO analysis. The KEGG annotation analysis data reveal that these miRNAs plays important in various Cancer signaling (e.g Renal, Pancreatic, Prostate, Colorectal, Melanoma ), Hippo signaling pathway, cardiomyopathy, Wnt signaling, Circadian rhythm, stem cell signaling, Adrenergic signaling in cardiomyocytes and number of other signaling pathways ([Table 5](#T5-ad-11-3-509){ref-type="table"}). GO analysis data showed more than 72 biological processes were associated with the miRNAs targeting COVID-19 ([Table 6](#T6-ad-11-3-509){ref-type="table"}). The biological processes such as organelle, ion binding, cellular, biosynthesis process, protein complex, immune response, and viral process are regulated by human miRNAs targeting the COVID-19 genome. Details of KEGG annotation and GO analysis are shown in [Table 5](#T5-ad-11-3-509){ref-type="table"}, and [Table 6](#T6-ad-11-3-509){ref-type="table"}, respectively.

DISCUSSION
==========

Host cellular miRNAs are known to play an antiviral role in the number of published studies \[[@b18-ad-11-3-509]-[@b23-ad-11-3-509]\]. In this study, we performed *in silico* analysis of human cellular miRNAs targeting SARS and COVID-19 (isolates) genome and identified some novel miRNAs. We identified number (558) of common human cellular miRNAs targeting both SARS and COVID-19 genome. Top 10 common miRNAs have a target score of ≥95 (target score between 99-95), and each miRNA contains more than at least ten sites in the targeting viral genome ([Table 3](#T3-ad-11-3-509){ref-type="table"}), indicating possible antiviral property for coronavirus infection (for both SARS and COVID-19). It will be interesting to verify these miRNA *in-vitro* and *in-vivo* animal models to use as a therapeutic target in the future. Cocktail of multiple miRNAs mimics through the intranasal route will be useful in coronavirus infection. These human miRNAs targeting coronavirus can be useful to combat any future outbreaks. In a previous report, host cellular miRNAs-181 binds to the ORF-4 region at the viral genome of porcine reproductive and respiratory syndrome virus (PRRSV) to inhibit its replication \[[@b17-ad-11-3-509]\]. One step further, Guo et al. (2013) delivered intranasal inhalation of miR-181 mimics to slow down the progression of PRRSV in an experimental porcine model \[[@b17-ad-11-3-509]\]. Another study used intranasal inoculation of miR-130 mimic to protect piglets from lethal challenge of PRRSV \[[@b30-ad-11-3-509]\]. Similarly, the intranasal administration of chemically modified five miRNA mimics protected mice from H1N1 viral infection \[[@b31-ad-11-3-509]\].

###### 

Human miRNAs targeting the COVID-19 genome regulating GO pathway.

  GO Category                                                    p-value       \#genes   \#miRNAs
  -------------------------------------------------------------- ------------- --------- ----------
  organelle                                                      1.26E-49      980       64
  ion binding                                                    5.53E-28      611       64
  cellular nitrogen compound metabolic process                   1.82E-23      474       63
  biosynthetic process                                           1.36E-13      388       42
  neurotrophin TRK receptor signaling pathway                    7.06E-13      44        44
  protein binding transcription factor activity                  1.83E-12      75        29
  Fc-epsilon receptor signaling pathway                          5.76E-12      32        24
  protein complex                                                6.82E-11      385       64
  gene expression                                                4.82E-10      70        35
  cellular protein modification process                          7.10E-10      232       41
  molecular_function                                             7.10E-10      1552      66
  extracellular matrix disassembly                               1.72E-09      26        14
  viral process                                                  1.82E-09      60        49
  symbiosis, encompassing mutualism through parasitism           1.82E-09      66        49
  small molecule metabolic process                               4.04E-09      229       57
  catabolic process                                              1.70E-08      197       58
  collagen catabolic process                                     3.52E-08      22        12
  cellular component assembly                                    5.85E-08      141       36
  cellular_component                                             7.90E-08      1559      66
  macromolecular complex assembly                                1.77E-07      101       36
  blood coagulation                                              8.36E-07      55        26
  nucleic acid binding transcription factor activity             1.97E-06      107       38
  cytosol                                                        3.58E-06      267       57
  protein complex assembly                                       4.08E-06      88        48
  epidermal growth factor receptor signaling pathway             1.64E-05      31        23
  enzyme binding                                                 1.92E-05      130       51
  extracellular matrix organization                              2.18E-05      51        21
  nucleoplasm                                                    2.49E-05      122       56
  cellular protein metabolic process                             3.33E-05      49        29
  xenobiotic metabolic process                                   4.07E-05      23        21
  immune system process                                          4.82E-05      160       36
  nucleobase-containing compound catabolic process               6.69E-05      92        53
  endoplasmic reticulum lumen                                    0.000154305   29        16
  response to stress                                             0.000159934   210       39
  innate immune response                                         0.000224462   80        28
  microtubule organizing center                                  0.000453748   56        43
  Fc-gamma receptor signaling pathway involved in phagocytosis   0.00093232    12        17
  toll-like receptor TLR1:TLR2 signaling pathway                 0.001615504   11        15
  toll-like receptor TLR6:TLR2 signaling pathway                 0.001615504   11        15
  fibroblast growth factor receptor signaling pathway            0.001615504   26        23
  mitotic cell cycle                                             0.001685088   39        45
  glutathione derivative biosynthetic process                    0.001906053   7         12
  DNA metabolic process                                          0.00191818    79        34
  biological_process                                             0.00191818    1484      66
  phosphatidylinositol-mediated signaling                        0.002737027   20        22
  toll-like receptor 2 signaling pathway                         0.005968204   12        17
  cytoskeleton-dependent intracellular transport                 0.007263134   17        15
  toll-like receptor 4 signaling pathway                         0.007263134   14        17
  membrane organization                                          0.007346668   56        45
  cellular response to jasmonic acid stimulus                    0.007563711   3         1
  cell motility                                                  0.008091976   60        31
  G2/M transition of mitotic cell cycle                          0.010059905   20        36
  cell-cell signaling                                            0.010959215   65        31
  platelet degranulation                                         0.011941199   11        15
  protein N-linked glycosylation via asparagine                  0.012823473   14        14
  homeostatic process                                            0.013223078   81        27
  post-translational protein modification                        0.013916886   18        20
  toll-like receptor 10 signaling pathway                        0.015857167   9         14
  cell death                                                     0.015857167   85        25
  substrate-dependent cell migration, cell extension             0.018717628   5         9
  nervous system development                                     0.019812789   51        26
  toll-like receptor 9 signaling pathway                         0.021790835   10        16
  RNA binding                                                    0.021790835   168       42
  platelet activation                                            0.023223454   22        20
  extracellular matrix structural constituent                    0.034117778   16        4
  transcription coactivator activity                             0.034117778   41        23
  cytoskeletal protein binding                                   0.036370846   71        34
  toll-like receptor 5 signaling pathway                         0.039177086   9         14
  axon guidance                                                  0.040371436   49        21
  cAMP metabolic process                                         0.043778349   3         9
  TRIF-dependent toll-like receptor signaling pathway            0.045227284   9         14

###### 

List of selected human miRNAs targeting the COVID-19 genome down-regulated with age and underlying conditions.

  miRNA         Decrease Expression in age related diseases (Human)   Reference
  ------------- ----------------------------------------------------- ------------------------------------------
  miR-15b-5p    Coronary Artery Disease                               Zhu et al 2017 \[[@b37-ad-11-3-509]\]
  miR-15a-5p    Kidney disease                                        Shang et al 2019 \[[@b38-ad-11-3-509]\]
  miR-548c-5p   Colorectal Cancer                                     Peng et al 2018 \[[@b49-ad-11-3-509]\]
  miR-548d-3p   Osteosarcoma                                          Chen et al 2019 \[[@b50-ad-11-3-509]\]
  miR-409-3p    Osteosarcoma                                          Wu et al 2019 \[[@b51-ad-11-3-509]\]
  miR-30b-5p    Plasma (Aging)                                        Hatse et al 2014 \[[@b52-ad-11-3-509]\]
  miR-505-3p    Prostate cancer                                       Tang et al 2019 \[[@b53-ad-11-3-509]\]
  miR-520c-3p   Obesity/diabetes                                      Ortega et al 2013 \[[@b39-ad-11-3-509]\]
  miR-30e-3p    Myocardial Injury                                     Wang et al 2017 \[[@b40-ad-11-3-509]\]
  miR-23c       Hepatocellular carcinoma                              Zhang et al 2018 \[[@b41-ad-11-3-509]\]
  miR-30d-5p    Non-small cell lung cancer                            Gao et al, 2018 \[[@b42-ad-11-3-509]\]
  miR-4684-3p   Colorectal cancer                                     Wu et al, 2015 \[[@b43-ad-11-3-509]\]
  miR-518a-5p   Gastrointestinal tumors                               Shi et al, 2016 \[[@b44-ad-11-3-509]\]

In humans, coronavirus infection is pervasive and usually causes common cold-like symptoms, but some of them can lead to serious illness. Previous coronavirus outbreak in 2002, known as SARS-CoV spread worldwide but was contained quickly \[[@b9-ad-11-3-509]\]. On the other hand, the current coronavirus (COVID-19) is highly contagious and spread worldwide rapidly and became a global pandemic \[[@b8-ad-11-3-509],[@b11-ad-11-3-509]\]. It will be interesting to know what separates these two viruses based on the genomic sequence. Ours ([Table 2](#T2-ad-11-3-509){ref-type="table"} and [Fig. 1](#F1-ad-11-3-509){ref-type="fig"}) and other data \[[@b32-ad-11-3-509]-[@b34-ad-11-3-509]\] of SARS-CoV and COVID-19 genome sequence analysis showed sequence homology of around \~78.7%, which was obvious, but our miRNA target scan data showed striking results. We found considerable changes in the number of human miRNAs targeting SARS-CoV (848 miRNAs) and COVID-19 (\~873 miRNAs). Moreover, we also found unique miRNAs for SARS-CoV (290 miRNAs) and COVID-19 (315 miRNAs) isolates. At nucleotide ([Table 2](#T2-ad-11-3-509){ref-type="table"}) and phylogenetic levels ([Fig. 1](#F1-ad-11-3-509){ref-type="fig"}), both viruses look closely related, but host cellular miRNAs target comparison differences are much more significant. This might be one of the reasons for COVID-19 to increase infectivity and easy viral propagation compared to SARS-CoV. The COVID-19 recent isolates (twenty-nine different isolates) are closely related at nucleotide, phylogenetic ([Fig. 1](#F1-ad-11-3-509){ref-type="fig"} and [Table 2](#T2-ad-11-3-509){ref-type="table"}), and host cellular miRNAs target level ([Fig. 2](#F2-ad-11-3-509){ref-type="fig"} and [Supplementary Table 2](#SD1-ad-11-3-509){ref-type="supplementary-material"}). The Netherland (EPI_ISL_422601), Australia (EPI_ISL_413214), and Wuhan (EPI_ISL_403931) isolates have more mutation and few different host cellular miRNAs targeting sites compared to other 26 COVID-19 isolates ([Table 4](#T4-ad-11-3-509){ref-type="table"}). In our study, we used 29 isolates from different geographical reagion, which informs that COVID-19 nucleotide sequences and thus the human miRNAs target sites are not changing among the isolates/viruses ([Table 4](#T4-ad-11-3-509){ref-type="table"}). In most of the COVID-19 cases, the virus entered a country from different geographical locations. At the time of writing this paper, only the USA and China had sequenced multiple viruses isolates from a different region. There is a need to sequence more of the COVID-19 viral genome from different parts of each country before coming to any conclusion.

The most important and striking feature of COVID-19 is the increased case fatality rate in aged individuals. The CDC reports 45% of cases requiring hospitalization are patients ≥65 years old \[[@b12-ad-11-3-509]\]. Furthermore, 80% of COVID-19 related deaths occur in these patients (≥65 years old) \[[@b12-ad-11-3-509]\]. Moreover, individuals with underlying conditions such as cardiovascular, chronic lung disease, diabetes, kidney, liver diseases, and cancer are at higher risk for severe illness and mortality. On the contrary, \<1% mortality is observed in patients between 20-54 years of age or younger \[[@b12-ad-11-3-509]\]. Based on miRNA target analysis and published literature, we hypothesized that the COVID-19 genome replicates and propagates viral particles easily in the aged individuals compared to younger due to the overall low abundance of miRNA expression with age. Recent human studies reported that the overall expression of miRNAs levels goes down with age \[[@b16-ad-11-3-509], [@b35-ad-11-3-509], [@b36-ad-11-3-509]\]. For example, Huan et al. (2018) reported that 81% (103 miRNAs) microRNAs were negatively, and 19% (24 miRNAs) positively correlated with age in human peripheral blood \[[@b36-ad-11-3-509]\]. We speculate that in younger individuals with COVID-19 infection, host cellular miRNAs bind to the complementary site of the viral RNA genome and prevent its replication; however, in an aged individual, this mechanism is not that efficient leads to accumulation of viral particle and severe illness. This might be true for underlying conditions as well. Some of the miRNAs targeting the COVID-19 genome showed low abundance (down-regulated) with some underlying conditions ([Table 7](#T7-ad-11-3-509){ref-type="table"}). For example, miR-15b-5p (Coronary artery disease) \[[@b37-ad-11-3-509]\], miR-15a-5p (Kidney disease) \[[@b38-ad-11-3-509]\], miR-520c-3p (obesity/diabetes) \[[@b39-ad-11-3-509]\], miR-30e-3p (Myocardial Injury) \[[@b40-ad-11-3-509]\], miR-23c (hepatocellular carcinoma) \[[@b41-ad-11-3-509]\], miR-30d-5p (non-small cell lung cancer) \[[@b42-ad-11-3-509]\], miR-4684-3p (colorectal cancer) 43\], and miR-518a-5p (Gastrointestinal stromal tumors) \[[@b44-ad-11-3-509]\] down-regulated in pathophysiological condition.

To identify the biological relevance of COVID-19 targeting human cellular miRNAs, KEGG pathway annotation, and GO analysis was performed on target gene pools. KEGG annotation data showed that COVID-19 targeting human miRNAs plays an important role in various cancer signaling, Hippo signaling pathways, cardiac (e.g cardiomyopathy, Adrenergic signaling in cardiomyocytes), cell cycle, FoxO and number of other signaling pathways ([Table.5](#T5-ad-11-3-509){ref-type="table"}). Furthermore, GO pathway annotation analysis showed that the COVID-19 targeting human miRNAs involved in important signaling dysregulated during age-related complications, such as biosynthesis, metabolic, cellular protein modification, and cellular component assembly. Most importantly, we also found that signaling related to immune response, Fc-epsilon receptor signaling pathway, viral process, and symbiosis, encompassing mutualism through parasitism signaling affected by the COVID-19 targeting human cellular miRNAs ([Table.6](#T6-ad-11-3-509){ref-type="table"}). The signaling mentioned above is important to fight against viral infections \[[@b45-ad-11-3-509]-[@b48-ad-11-3-509]\]. Both KEGG and GO pathway analysis revealed that COVID-19 targeting human cellular miRNAs are involved in the number of age-related complications. Impaired GO and KEGG pathways may be due to low abundance miRNA and might be one of the contributing factors for the increasing severity and mortality of the COVID-19 infection in aged individuals and with other underlying conditions.

The dual role of host cellular miRNAs cannot be denied in the viral replication or inhibition. Host miRNAs can have both functions, antiviral, which is beneficial to host, or miRNA-viral genome interaction can increase stability and beneficiary for viral propagation \[[@b18-ad-11-3-509], [@b20-ad-11-3-509], [@b22-ad-11-3-509]\]. In a viral infection, we hypothesized that host cellular miRNAs predominantly have antiviral activity. Though possible, positive regulation of viral genome translation by miRNAs is less likely. Our data and hypothesis are based on *in silico* analysis and realize that not all miRNAs targets will be real. Considering the many miRNAs targets identified in our *in-silico* analysis, even if 5% of total miRNAs targets are real (based on target score), it is possible that these could be used for therapeutic purposes. Further, *in vitro* and *in vivo* studies will be needed to validate some of these targets. However, in view of the current lack of effective treatment strategies, innovative approaches need to be considered.
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